---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-057228"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T21:54:03.176691+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sagimet Biosciences appoints Thierry Chauche as CFO, effective May 6, 2024

## Summary
- Thierry Chauche named CFO, replacing interim CFO Joseph Oriti who resigned.
- Chauche receives $480k base salary, 40% target bonus, and option grant valued at $2M (Black-Scholes).
- Option vests over 4 years (25% cliff at 1 year, then monthly).
- Severance: 6 months base salary (12 months during change in control), plus COBRA and equity acceleration.
- Chauche previously CFO of Provention Bio and held roles at Alexion, Intercept, Novartis.

## SEC filing metadata
- accession: 0001104659-24-057228
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924057228/0001104659-24-057228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924057228/tm2413539d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-057228
- JSON: https://secwatch.observer/filing/0001104659-24-057228.json
- Plain text: https://secwatch.observer/filing/0001104659-24-057228.txt

## Key facts
- Executive change
  Thierry Chauche was appointed as Chief Financial Officer at Sagimet Biosciences Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 3, 2024, the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) appointed Thierry Chauche as the Company’s Chief Financial Officer, effective May 6, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465924057228/0001104659-24-057228-index.htm
- Executive change
  Joseph Oriti resigned as interim Principal Financial Officer and interim Principal Accounting Officer at Sagimet Biosciences Inc..
  - Action: resigned
  - Role: interim Principal Financial Officer and interim Principal Accounting Officer
  source text: On May 5, 2024, Joseph Oriti, the Company’s interim Principal Financial Officer and interim Principal Accounting Officer resigned in connection with Mr. Chauche’s appointment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465924057228/0001104659-24-057228-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.